Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Review uri icon

Overview

abstract

  • Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth.

publication date

  • November 1, 1993

Research

keywords

  • Breast Neoplasms
  • Molecular Biology
  • Tamoxifen

Identity

Scopus Document Identifier

  • 0027361914

PubMed ID

  • 8239980

Additional Document Info

volume

  • 128

issue

  • 11